{"disease":{"id":"resistance","name":"resistance"},"drugs":{"marketed":[{"drug_id":"ponatinib-hydrochloride","indication_name":"CP-CML with resistance or intolerance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PONATINIB HYDROCHLORIDE","company_name":"","drug_phase":"marketed","molecular_target":"ABL, T315I mutant ABL, VEGFR, PDGFR, FGFR, EPH receptors, SRC family, KIT, RET, TIE2, FLT3","drug_class":"","quality_score":53,"revenue":null,"mechanism":"Ponatinib inhibits multiple kinases, including ABL and its T315I mutant, reducing tumor size in mice."},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, and/or CDK4/6 inhibitor resistance","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, and/or prior endocrine therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, and/or prior chemotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, and/or prior radiotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, and/or prior surgery","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, and/or prior hormone therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, and/or prior targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, and/or prior immunotherapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, and/or prior chemotherapy with a taxane","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, and/or prior chemotherapy with a platinum agent","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, and/or prior chemotherapy with a microtubule inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, and/or prior chemotherapy with a PARP inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, and/or prior chemotherapy with a mTOR inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, and/or prior chemotherapy with a HER2-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, and/or prior chemotherapy with a PIK3CA-targeted therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, and/or prior chemotherapy with a hormone receptor antagonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, and/or prior chemotherapy with a hormone receptor agonist","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, and/or prior chemotherapy with a selective estrogen receptor degrader","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, and/or prior chemotherapy with a selective estrogen receptor modulator","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, and/or prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"pf-07850327-arv-471-vepdegestrant","indication_name":"Breast cancer with a PIK3CA mutation, hormone receptor-positive, HER2-negative, ESR1 mutation, TP53 mutation, CDK4/6 inhibitor resistance, prior endocrine therapy, prior chemotherapy, prior radiotherapy, prior surgery, prior hormone therapy, prior targeted therapy, prior immunotherapy, prior chemotherapy with a taxane, prior chemotherapy with a platinum agent, prior chemotherapy with a microtubule inhibitor, prior chemotherapy with a PARP inhibitor, prior chemotherapy with a CDK4/6 inhibitor, prior chemotherapy with a mTOR inhibitor, prior chemotherapy with a HER2-targeted therapy, prior chemotherapy with a PIK3CA-targeted therapy, prior chemotherapy with a hormone receptor antagonist, prior chemotherapy with a hormone receptor agonist, prior chemotherapy with a selective estrogen receptor degrader, prior chemotherapy with a selective estrogen receptor modulator, prior chemotherapy with a cyclin-dependent kinase 4/6 inhibitor, and/or prior chemotherapy with a CDK4/6 inhibitor and/or a PIK3CA inhibitor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07850327, ARV-471, vepdegestrant","generic_name":"pf-07850327-arv-471-vepdegestrant","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Estrogen Receptor (ER)","drug_class":"Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Degraders (SERDs), Selective Estrogen Receptor Covalent Antagonists (SERCAs)","quality_score":55,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":23,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06358872","title":"Azithromycin for Child Survival in Niger II","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":3300000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT04662047","title":"The Impact of Air Pollution on the Consumption of Antimicrobials in the General Population","phase":"","overall_status":"UNKNOWN","enrollment_count":3249128,"lead_sponsor_name":"Hospital Universitari de Bellvitge","has_results":false},{"nct_id":"NCT04224987","title":"Azithromycin for Child Survival in Niger: Mortality and Resistance Trial","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":864493,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT05288023","title":"Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":169707,"lead_sponsor_name":"University of California, San Francisco","has_results":true},{"nct_id":"NCT07082465","title":"Epidemiology of Antimicrobial-use and Antimicrobial-resistant Infections in Four Hospitals in Thailand","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":108000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT05813821","title":"7-VINCut Antibiotic Stewardship Intervention to Decrease Duration of Antibiotic Treatment and Carbapenem Use in Surgery","phase":"NA","overall_status":"COMPLETED","enrollment_count":32499,"lead_sponsor_name":"Hospital de Granollers","has_results":false},{"nct_id":"NCT05874635","title":"Signos DM2 Empowerment Study (SIGNOS-CGM-EMPOWER-201-2022)","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Signos Inc","has_results":false},{"nct_id":"NCT05451836","title":"N-of-1 Trials of Interventions to Improve Decision-making for Antibiotic Use","phase":"NA","overall_status":"COMPLETED","enrollment_count":15157,"lead_sponsor_name":"Tan Tock Seng Hospital","has_results":false},{"nct_id":"NCT07336563","title":"ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":10000,"lead_sponsor_name":"Jarosław Drobnik","has_results":false},{"nct_id":"NCT06044272","title":"Antimicrobial Resistance in Hospitals From Meta, Colombia","phase":"","overall_status":"COMPLETED","enrollment_count":10000,"lead_sponsor_name":"Hospital Departamental de Villavicencio","has_results":false},{"nct_id":"NCT07431190","title":"British Columbia Prescriber Feedback Program - Antimicrobial Resistance","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":7626,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT05378880","title":"Optimising Community Antibiotic Use and Infection Control With Behavioural Interventions in Burkina Faso and DR Congo","phase":"NA","overall_status":"COMPLETED","enrollment_count":5532,"lead_sponsor_name":"Institute of Tropical Medicine, Belgium","has_results":false},{"nct_id":"NCT06853535","title":"Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":5138,"lead_sponsor_name":"Sichuan Provincial People's Hospital","has_results":false},{"nct_id":"NCT03352167","title":"Antibiotic Resistance in Danish EDs.","phase":"","overall_status":"COMPLETED","enrollment_count":5117,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT07226557","title":"Cefiderocol vs Best Available Therapy for Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex Infections: A Target Trial Emulation","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Institutes of Health Clinical Center (CC)","has_results":false},{"nct_id":"NCT06356285","title":"Testing New Ways to Name Antimicrobial Resistance","phase":"NA","overall_status":"COMPLETED","enrollment_count":4296,"lead_sponsor_name":"Imperial College London","has_results":true},{"nct_id":"NCT07237971","title":"Cocreating Action to Improve Rationality in the Health System","phase":"NA","overall_status":"RECRUITING","enrollment_count":4000,"lead_sponsor_name":"Universidad Miguel Hernandez de Elche","has_results":false},{"nct_id":"NCT03382470","title":"Impact of Antimicrobial Stewardship Programs in the Global Setting","phase":"","overall_status":"COMPLETED","enrollment_count":3115,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT03937245","title":"Epidemiology and Determinants of Outcomes of Hospital Acquired Blood Stream Infections in the Intensive Care","phase":"","overall_status":"COMPLETED","enrollment_count":3058,"lead_sponsor_name":"Outcome Rea","has_results":false},{"nct_id":"NCT04015726","title":"Secular Trends in the Prevalence of Cardiometabolic Risk Factors Among Teenage School Children in Urban South India","phase":"","overall_status":"UNKNOWN","enrollment_count":2815,"lead_sponsor_name":"India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals","has_results":false},{"nct_id":"NCT04817280","title":"COVID-19 in Polish Ice Swimmers.","phase":"","overall_status":"COMPLETED","enrollment_count":2534,"lead_sponsor_name":"Wroclaw Medical University","has_results":false},{"nct_id":"NCT04028830","title":"Impact on Antibiotic Prescriptions of a Bundle Intervention Conducted by Medical Representatives in General Practitioner Facilities, Based on Operational Demonstration of an Internet Decision Support Tool: Antibioclic","phase":"NA","overall_status":"COMPLETED","enrollment_count":2501,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT00341003","title":"Severe Malaria and Anti-malarial Drug Resistance in Cambodia","phase":"","overall_status":"COMPLETED","enrollment_count":2090,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03310502","title":"Variation of Genes Controlling Carbohydrate and Lipid Metabolism","phase":"","overall_status":"UNKNOWN","enrollment_count":2050,"lead_sponsor_name":"Turku University Hospital","has_results":false},{"nct_id":"NCT06694012","title":"Osaka Cardiometabolic Epidemiological Study: Ohtori Study Part 2","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Osaka Metropolitan University","has_results":false},{"nct_id":"NCT07274345","title":"Prevalence and Risk Factors of Antiviral Resistance in Egyptian HBV Patients","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Amira Mohamed Zidan","has_results":false},{"nct_id":"NCT05247112","title":"Prevalence and Trends of Antimicrobial Resistance of Helicobacter Pylori in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Seoul National University Bundang Hospital","has_results":false},{"nct_id":"NCT03174236","title":"First Line Antimicrobials in Children With Complicated Severe Acute Malnutrition","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of Oxford","has_results":false},{"nct_id":"NCT04388293","title":"Using Antibiotics Wisely - An Antimicrobial Stewardship Program","phase":"","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"University of British Columbia","has_results":false},{"nct_id":"NCT03742011","title":"Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Guangzhou Women and Children's Medical Center","has_results":false},{"nct_id":"NCT03971877","title":"Detection of Colistin-resistant Isolates From Patients of Intensive Care Units and Oncohaematology Wards.","phase":"","overall_status":"COMPLETED","enrollment_count":1934,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05641025","title":"Prediction of Multidrug-resistant Bacterial Infection in Patients with Cirrhosis","phase":"","overall_status":"COMPLETED","enrollment_count":1774,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT00340132","title":"Cross-Sectional and Longitudinal Studies of \"Pre-Diabetes\" in the Pima Indians","phase":"","overall_status":"COMPLETED","enrollment_count":1759,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT04268342","title":"Gonorrhoea Resistance Assessment by Nucleic Acid Detection (GRANDII)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1626,"lead_sponsor_name":"The University of Queensland","has_results":false},{"nct_id":"NCT07234331","title":"A Multicentre Study of Wastewater and Antibiotic Resistance in Care Homes.","phase":"","overall_status":"RECRUITING","enrollment_count":1600,"lead_sponsor_name":"Nantes University Hospital","has_results":false},{"nct_id":"NCT06882070","title":"ROTA-biotic: Measuring the Impact of Rotavirus Vaccines on Paediatric Antibiotic Usage","phase":"","overall_status":"COMPLETED","enrollment_count":1600,"lead_sponsor_name":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","has_results":false},{"nct_id":"NCT05231187","title":"T2Resistance - Detection of Resistance Related Genes","phase":"","overall_status":"COMPLETED","enrollment_count":1566,"lead_sponsor_name":"T2 Biosystems","has_results":false},{"nct_id":"NCT05734391","title":"Surveillance of Healthcare-associated Infections & Antimicrobial Resistance","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":1500,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT03752476","title":"Impact of Number of Rank of B-lactam Antibiotics on Emergence on Multidrug Resistant Bacteria","phase":"","overall_status":"UNKNOWN","enrollment_count":1300,"lead_sponsor_name":"Centre Hospitalier Universitaire de Besancon","has_results":false},{"nct_id":"NCT06511492","title":"Longitudinal Surveillance of Rectal Colonization and Transmission by Resistant Bacteria in Acutely Decompensated Cirrhosis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":1289,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT07321288","title":"Machine Learning-Based Prediction of Insulin Resistance in Psoriasis Patients Emphasizing Interpretability","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1265,"lead_sponsor_name":"Chinese PLA General Hospital","has_results":false},{"nct_id":"NCT03557021","title":"Impact of HIV Drug Resistance Testing, and Subsequent Change to an Individualized Therapy in Tanzania","phase":"NA","overall_status":"UNKNOWN","enrollment_count":1250,"lead_sponsor_name":"Medical Mission Institute, Germany","has_results":false},{"nct_id":"NCT03301519","title":"Genetics of Beta Cell Failure in Mexican Americans","phase":"","overall_status":"COMPLETED","enrollment_count":1250,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT05303662","title":"Prevalence of Multidrug Resistant Micro-organism Carriage in Patients Undergoing an ERCP in Four Different Countries","phase":"","overall_status":"COMPLETED","enrollment_count":1244,"lead_sponsor_name":"Marco J. Bruno","has_results":false},{"nct_id":"NCT05195866","title":"CRP for Respiratory Diagnosis in Kyrgyz Pediatric Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":1204,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT05089760","title":"Microbiology, Antimicrobial Resistance and Outcomes of Neonatal Sepsis in China","phase":"","overall_status":"UNKNOWN","enrollment_count":1200,"lead_sponsor_name":"Children's Hospital of Fudan University","has_results":false},{"nct_id":"NCT00001987","title":"Genetic Studies of Insulin and Diabetes","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","has_results":false},{"nct_id":"NCT05285657","title":"Algorithm Using a Rapid Diagnostic Test for the Management of Childhood Febrile Diseases.","phase":"NA","overall_status":"COMPLETED","enrollment_count":1176,"lead_sponsor_name":"Institut de Recherche en Sciences de la Sante, Burkina Faso","has_results":false},{"nct_id":"NCT05410652","title":"Helicobacter Pylori 23S rRNA/gyrA Gene Mutation Detection Kit (Fluorescence PCR Fusion Curve Method)","phase":"","overall_status":"COMPLETED","enrollment_count":1176,"lead_sponsor_name":"Nanjing First Hospital, Nanjing Medical University","has_results":false},{"nct_id":"NCT03408678","title":"Determinants of Type 2 Diabetes Risk in Middle-aged Black South African Men and Women","phase":"","overall_status":"COMPLETED","enrollment_count":1025,"lead_sponsor_name":"University of Witwatersrand, South Africa","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}